Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

MDS Selling MDS Pharma Services

By Drug Discovery Trends Editor | September 2, 2009

MDS Inc. has announced its intent to sell MDS Pharma Services, a leading provider of innovative drug discovery and early stage development solutions. Discussions are underway with interested parties who are attracted by our position as a Top Three provider in the Discovery through Phase IIa clinical proof-of-concept space, and who want to build on our strong foundation.

The intended separation from MDS Inc. is a new beginning for MDS Pharma Services and a continuation of our journey to market leadership as an early stage CRO. Our clients will continue to benefit from our leadership position in molecular screening, profiling, drug safety assessment, early clinical research and bioanalysis. And our employees will continue to execute our strategy to focus on Discovery through Phase IIa and to deliver Quality On Time client service. No disruptions in client service are anticipated as a result of this proposed change in ownership. In order to foster continuity and stability during the interim, the MDS Pharma Services leadership team will remain in place through the transition to new ownership.

MDS Inc. will continue to honor current and future commitments to our clients and to keep them informed as we move forward on our new path. By focusing on Discovery through Phase IIa, MDS Pharma Services is playing to its strengths in early stage, and like others in our industry, has shed non-core assets to concentrate on what we do best.

As previously announced, the MDS Pharma Services late stage operations are being divested.  The Phase IIb-IV Global Clinical Development organization has been acquired by INC Research and a suitable buyer is being sought for Global Central Labs. Discussions with interested parties are underway. The sale of MDS Pharma Services is not contingent on the Global Central Labs divestiture.

MDS Pharma Services offers one of the outsourcing industry’s broadest service portfolios spanning Discovery through Phase IIa, with one of the largest Early Stage bed capacities in the industry with facilities in Europe and North America, and over 1,700 skilled employees at 10 facilities in six countries in Asia, Europe and North America, as well as an auxiliary office in Tokyo.

Date: September 2, 2009
Source: MDS Pharma Services 


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE